Investor Presentaiton
81
Investor presentation
Full year 2022
Haemophilia is a rare disease with severe unmet medical needs
but the market is highly competitive
Recombinant haemophilia product sales
DKK billion
50
40
30
20
10
0
-2%
+7%
+9%
Novo NordiskⓇ
2017
2021
2017
Haemophilia with inhibitors
Haemophilia A
Patients1
~ 7,000
~ 185,000
2021
2017
2021
Haemophilia B
~ 38,000
NovoSevenⓇ
susoctocog alfa²
Coagil³
Feiba4
Hemlibra
NovoEight®
EsperoctⓇ
Eloctate
Xyntha/Refacto
Helixate/Afstyla
RefixiaⓇ/RebinynⓇ
Kogenate/Kovaltry/Jivi
Advate/Adynovate
Hemlibra
Benefix
Rixubis
Idelvion
Alprolix
1 Total diagnosed patients in segment, WFH annual survey 2021 (numbers may be understated as 118 out of 147 countries responded); 2 Obizur only indicated for acquired haemophilia; 3 Plasma-derived; 4 Part of the Hemlibra sales is used for treatment of
haemophilia A patients in 2021
Source: Company reported sales and Evaluate PharmaView entire presentation